TW202515561A - 用於治療癌症之醫藥組成物 - Google Patents
用於治療癌症之醫藥組成物 Download PDFInfo
- Publication number
- TW202515561A TW202515561A TW113124518A TW113124518A TW202515561A TW 202515561 A TW202515561 A TW 202515561A TW 113124518 A TW113124518 A TW 113124518A TW 113124518 A TW113124518 A TW 113124518A TW 202515561 A TW202515561 A TW 202515561A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- days
- pharmaceutical composition
- salt
- daily dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245632P | 2015-10-23 | 2015-10-23 | |
| US62/245,632 | 2015-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202515561A true TW202515561A (zh) | 2025-04-16 |
Family
ID=57349101
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW113124518A TW202515561A (zh) | 2015-10-23 | 2016-10-21 | 用於治療癌症之醫藥組成物 |
| TW112100559A TW202332444A (zh) | 2015-10-23 | 2016-10-21 | 用於治療癌症之醫藥組成物 |
| TW105134053A TWI806822B (zh) | 2015-10-23 | 2016-10-21 | 製備治療癌症之醫藥組成物之用途 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112100559A TW202332444A (zh) | 2015-10-23 | 2016-10-21 | 用於治療癌症之醫藥組成物 |
| TW105134053A TWI806822B (zh) | 2015-10-23 | 2016-10-21 | 製備治療癌症之醫藥組成物之用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20180296547A1 (enExample) |
| EP (1) | EP3364972A1 (enExample) |
| JP (4) | JP6855472B2 (enExample) |
| KR (1) | KR20180064540A (enExample) |
| CN (2) | CN113521069A (enExample) |
| HK (1) | HK1253098A1 (enExample) |
| TW (3) | TW202515561A (enExample) |
| WO (1) | WO2017069289A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170134462A (ko) * | 2015-04-13 | 2017-12-06 | 다이이찌 산쿄 가부시키가이샤 | Mdm2 저해제와 btk 저해제의 병용 치료법 |
| CN113521069A (zh) * | 2015-10-23 | 2021-10-22 | 第一三共株式会社 | 用于治疗癌症的mdm2抑制剂的给药方案 |
| US10409015B1 (en) | 2015-12-15 | 2019-09-10 | Optomind Inc. | Optical receiving device including focusing lens and reflector mounted to housing body and collimating lens mounted to housing cover |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CA3226022A1 (en) * | 2021-08-09 | 2023-02-16 | Boehringer Ingelheim International Gmbh | Oral composition comprising a mdm2-antagonist for cancer therapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007107545A1 (en) * | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53 |
| US20100068174A1 (en) * | 2006-08-21 | 2010-03-18 | Synta Pharmaceuticals Corp. | Combination with bis (thiohydrazide amides) for treating cancer |
| ES2382701T3 (es) * | 2007-09-21 | 2012-06-12 | Janssen Pharmaceutica, N.V. | Inhibidores de la interacción entre MDM2 y p53 |
| KR101779644B1 (ko) | 2011-03-10 | 2017-09-18 | 다이이찌 산쿄 가부시키가이샤 | 디스피로피롤리딘 유도체 |
| CA2858565A1 (en) * | 2011-12-07 | 2013-07-04 | Duke University | Methods of identifying and using mdm2 inhibitors |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| JP5958208B2 (ja) * | 2012-09-10 | 2016-07-27 | 凸版印刷株式会社 | 包装袋 |
| US10030028B2 (en) * | 2013-09-04 | 2018-07-24 | Daiichi Sankyo Company, Limited | Method for producing a spirooxindole derivative |
| JP2017508442A (ja) * | 2014-01-14 | 2017-03-30 | 第一三共株式会社 | Ｍｄｍ２阻害剤に対する感受性と関連する遺伝子シグネチャー |
| CA2976752C (en) * | 2015-02-20 | 2019-12-17 | Daiichi Sankyo Company, Limited | Method for treating cancer by combined use |
| KR20170134462A (ko) | 2015-04-13 | 2017-12-06 | 다이이찌 산쿄 가부시키가이샤 | Mdm2 저해제와 btk 저해제의 병용 치료법 |
| CN113521069A (zh) * | 2015-10-23 | 2021-10-22 | 第一三共株式会社 | 用于治疗癌症的mdm2抑制剂的给药方案 |
-
2016
- 2016-10-21 CN CN202110980773.0A patent/CN113521069A/zh active Pending
- 2016-10-21 US US15/769,054 patent/US20180296547A1/en not_active Abandoned
- 2016-10-21 TW TW113124518A patent/TW202515561A/zh unknown
- 2016-10-21 TW TW112100559A patent/TW202332444A/zh unknown
- 2016-10-21 KR KR1020187014440A patent/KR20180064540A/ko not_active Ceased
- 2016-10-21 WO PCT/JP2016/081975 patent/WO2017069289A1/en not_active Ceased
- 2016-10-21 EP EP16798291.7A patent/EP3364972A1/en active Pending
- 2016-10-21 HK HK18112485.7A patent/HK1253098A1/zh unknown
- 2016-10-21 JP JP2018520638A patent/JP6855472B2/ja active Active
- 2016-10-21 CN CN201680061650.4A patent/CN108135892A/zh active Pending
- 2016-10-21 TW TW105134053A patent/TWI806822B/zh active
-
2019
- 2019-03-06 US US16/293,926 patent/US11058673B2/en active Active
-
2021
- 2021-03-17 JP JP2021043154A patent/JP7192011B2/ja active Active
- 2021-05-18 US US17/323,636 patent/US20220071975A1/en active Pending
-
2022
- 2022-12-07 JP JP2022195270A patent/JP2023025214A/ja active Pending
-
2024
- 2024-08-21 JP JP2024139510A patent/JP2024164122A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI806822B (zh) | 2023-07-01 |
| JP2024164122A (ja) | 2024-11-26 |
| JP2021098750A (ja) | 2021-07-01 |
| HK1253098A1 (zh) | 2019-06-06 |
| US20190201386A1 (en) | 2019-07-04 |
| KR20180064540A (ko) | 2018-06-14 |
| JP2023025214A (ja) | 2023-02-21 |
| TW202332444A (zh) | 2023-08-16 |
| EP3364972A1 (en) | 2018-08-29 |
| JP7192011B2 (ja) | 2022-12-19 |
| TW201722427A (zh) | 2017-07-01 |
| WO2017069289A1 (en) | 2017-04-27 |
| CN108135892A (zh) | 2018-06-08 |
| US11058673B2 (en) | 2021-07-13 |
| JP6855472B2 (ja) | 2021-04-07 |
| US20220071975A1 (en) | 2022-03-10 |
| JP2018531273A (ja) | 2018-10-25 |
| US20180296547A1 (en) | 2018-10-18 |
| CN113521069A (zh) | 2021-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7192011B2 (ja) | がんを治療するためのｍｄｍ２阻害剤の投与計画 | |
| US11135201B2 (en) | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | |
| AU2016287508B2 (en) | Methods of treating solid tumors using nanoparticle MTOR inhibitor combination therapy | |
| JP2023071656A (ja) | ナノ粒子組成物のためのバイオマーカー | |
| JP2018521058A5 (enExample) | ||
| JP2020535173A (ja) | Ｈｓｐ９０阻害剤に関係する治療方法 | |
| JP6716585B2 (ja) | 結腸直腸癌の処置に使用するためのアピリモド | |
| JP2018531273A6 (ja) | がんを治療するためのｍｄｍ２阻害剤の投与計画 | |
| KR20230015888A (ko) | 사시투주맙 고비테칸 요법에 대한 바이오마커 | |
| CN115867669A (zh) | 监测kras突变的方法 | |
| CN114302746A (zh) | 包含抗cd25抗体药物缀合物和另一剂的组合疗法 | |
| US20240165112A1 (en) | Therapy for the treatment of cancer | |
| CN119947713A (zh) | 用于精准癌症治疗的组合物及精准癌症治疗方法 | |
| WO2024263966A2 (en) | Compositions comprising antineoplastons and methods of treating pancreatic cancer | |
| WO2024263963A2 (en) | Compositions comprising antineoplastons and methods of treating head and neck cancer | |
| WO2024263643A1 (en) | Compositions comprising antineoplastons and methods of treating breast cancer | |
| WO2024263960A2 (en) | Compositions comprising antineoplastons and methods of treating lung cancer | |
| WO2024263813A2 (en) | Compositions comprising antineoplastons and methods of treating colorectal cancer |